Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
04/2007
04/05/2007DE102005047561A1 Drug delivery system, useful to treat and/or prevent e.g. thromboembolic disease, comprises 5-chloro-N-(((5S)-2-oxo-3-(4-(3-oxo -4-morpholinyl)-phenyl)-1,3-oxazolidine-5-yl)-methyl)-2-thiophene carboxamide with fast release active substance
04/05/2007DE102005047308A1 Platinum compounds based on propane-1,3-diamine derivatives for treating carcinomas that are resistant to cis-platin, induce apoptosis but not by activation of caspase
04/05/2007DE102005046769A1 Ophthalmic composition, useful to treat eye diseases e.g. herpes simplex virus-epithelial keratitis, comprises brivudine, auxiliary materials and film former such as polyvinyl pyrrolidone, polyvinyl alcohol or polyacrylate
04/05/2007DE102005033902B3 Perfluoralkylhaltige Komplexe, Verfahren zu deren Herstellung, sowie deren Verwendung und diese enthaltende pharmazeutische Mittel Perfluoroalkyl-containing complexes, processes for their preparation, and their use and pharmaceutical compositions containing them
04/05/2007DE102004015752B4 Verwendung von Gabapentin-Laktam zur Behandlung renaler Erkrankungen Use of gabapentin-lactam for treatment of renal diseases
04/05/2007CA2850858A1 Compositions and methods for the intraocular transport of therapeutic agents
04/05/2007CA2762013A1 Granulation of pirfenidone and pharmaceutically acceptable excipients
04/05/2007CA2624686A1 Therapeutic molecules and their uses
04/05/2007CA2624535A1 Hepatocyte growth factor receptor splice variants and methods of using same
04/05/2007CA2624491A1 Novel azetidine compounds useful in the treatment of functional gastrointestinal disorders, ibs and functional dyspepsia
04/05/2007CA2624372A1 Microparticles with modified release of at least one active principle and oral galenic form comprising same
04/05/2007CA2624356A1 Skincare products
04/05/2007CA2624183A1 Thiophene derivatives as ppar agonists i
04/05/2007CA2624176A1 Condensed pyrazole derivatives as ppar agonists ii
04/05/2007CA2624162A1 Aryl-substituted nitrogen-containing heterocyclic compound
04/05/2007CA2624150A1 The use of phthalide derivatives
04/05/2007CA2624138A1 Method and composition for increasing the engraftment efficiency of stem cells
04/05/2007CA2624112A1 Methods for preparing core-shell composites having cross-linked shells and core-shell composites resulting therefrom
04/05/2007CA2624047A1 Kit for parenteral administration of lipophilic drug solutions
04/05/2007CA2624018A1 Milnacipran for the long-term treatment of fibromyalgia syndrome
04/05/2007CA2623965A1 5h-thieno (3,4-c) pyrrole-4, 6-dione derivatives against cell releasing tumor necrosis factor
04/05/2007CA2623958A1 2-heteroaryl-substituted indole derivative
04/05/2007CA2623957A1 Compositions for and methods of granzyme b inhibition
04/05/2007CA2623946A1 Sulfatides for treatment of autoimmune disorders
04/05/2007CA2623905A1 Estriol therapy for autoimmune and neurodegenerative diseases and disorders
04/05/2007CA2623882A1 Aerosol powder formulation comprising sieved lactose
04/05/2007CA2623764A1 Modulation of tlr-mediated immune responses using adaptor oligonucleotides
04/05/2007CA2623745A1 Hexahydro-cycloheptapyrazole cannabinoid modulators
04/05/2007CA2623678A1 Formulations with improved bioavailability, comprising a steroid derivative and a polyglycolysed glyceride
04/05/2007CA2623659A1 Targeted delivery of compounds using multimerization technology
04/05/2007CA2623646A1 4- (4-bromo-2-fluoroanilino) -6-methoxy-7- (1-methylpiperidin-4 -ylmethoxy) quinazoline monohydrate
04/05/2007CA2623533A1 Pharmaceutically acceptable salts and hydrates of risedronic acid
04/05/2007CA2623525A1 Tetrahydro-indazolyl cannabinoid modulators
04/05/2007CA2623523A1 Detection of lysophosphatidylcholine for prognosis or diagnosis of a systemic inflammatory condition
04/05/2007CA2623481A1 19,23,24,25,26,27-hexanor-1alpha-hydroxyvitamin d3
04/05/2007CA2623475A1 Combination of polychitosamine and fibrate for the prevention and treatment of hyperlipidemia
04/05/2007CA2623374A1 Imidazo [1,2-a] pyridine having anti-cell-proliferation activity
04/05/2007CA2623369A1 Fused heterocyclic compounds useful as kinase modulators
04/05/2007CA2623357A1 Inhibitors of ste20-like kinase (slk) and methods of modulating cell cycle progression and cell motility
04/05/2007CA2623350A1 Process for the stereoselective preparation of (-)-halofenate and intermediates thereof
04/05/2007CA2623294A1 2-aminoethoxyacetic acid derivatives and their use
04/05/2007CA2623252A1 Benzothiazole cyclobutyl amine derivatives and their use as histamine-3 receptors ligands
04/05/2007CA2623245A1 Amino-5- [4- (difluoromethoxy) phenyl] -5-phenylimidazolone compounds as inhibitors of the beta-secretase (bace)
04/05/2007CA2623228A1 Thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors
04/05/2007CA2623210A1 Ppar-gamma agonists for improvement of cognitive function in apoe4 negative patients
04/05/2007CA2623204A1 Combination of rosiglitazone and donepezil for improvement of cognitive function
04/05/2007CA2623072A1 Use of ibudilast for treating drug and behavioral addictions
04/05/2007CA2623063A1 N-(4-oxo-3,4-dihydroquinazolin-2-yl)butanamides as androgen receptor modulators
04/05/2007CA2623047A1 7-[2-[4-(6-fluoro-3-methyl-1,2-benzisoxazol-5-yl)-1-piperazinyl]ethyl]-2-(1-propynyl)-7h-pyrazolo-[4,3-e]-[1,2,4]-triazolo-[1,5-c]-pyrimidin-5 amine
04/05/2007CA2623040A1 Adenosine a2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
04/05/2007CA2623034A1 Carboxyamine compounds and their use in the treatment of hdac dependent diseases
04/05/2007CA2623026A1 Fused tetracyclic mglur1 antagonists as therapeutic agents
04/05/2007CA2622988A1 N-benzyl substituted pyridyl porphyrin compounds and methods of use thereof
04/05/2007CA2622701A1 Amino-aza-adamantane derivatives and methods of use
04/05/2007CA2622677A1 Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof
04/05/2007CA2622494A1 Diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors
04/05/2007CA2622492A1 Pesticide strips for control of mites in honeybees
04/05/2007CA2622475A1 Treatment of inflammation and vascular abnormalities of the eye
04/05/2007CA2622470A1 Prevention and treatment of gastrointestinal and bladder disorders associated with chemotherapy or radiation therapy using active vitamin d compounds
04/05/2007CA2622418A1 Indanylamines and their use for local anesthesia and chronic pain
04/05/2007CA2622001A1 Methods for treatment and prevention of otitis media using chemical penetration enhancers to facilitate transmembrane drug delivery into the middle ear
04/05/2007CA2622000A1 Quinolines and their therapeutic use
04/05/2007CA2621310A1 Sulfonamide derivative having pgd2 receptor antagonistic activity
04/05/2007CA2621261A1 Azepine inhibitors of janus kinases
04/05/2007CA2621255A1 Amido compounds and their use as pharmaceuticals
04/05/2007CA2620878A1 Theramutein modulators
04/05/2007CA2607583A1 Pantoprazole free acid form iii
04/05/2007CA2522411A1 Compositions and methods for cancer treatment
04/04/2007WO2007041637A2 Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
04/04/2007EP1770168A2 Compositions and methods for delivery of genetic material
04/04/2007EP1770093A1 Pyrido¬2,3-d|pyrimidine derivatives as phosphodiesterase inhibitors
04/04/2007EP1770092A1 Process for the preparation of 5-(4-(2-(N-methyl-N-(2-pyridyl)amino)ethoxy)benzyl)-2,4-thiazolidinedione
04/04/2007EP1770089A1 Pyranodibenzofuran derivatives with antifungal and antibacterial activity
04/04/2007EP1770083A1 Inorganic ion receptor-active compounds
04/04/2007EP1769821A1 Applicator for the delivery of topical formulations into mucosal cavities
04/04/2007EP1769819A2 Metered dose inhaler for fluticasone propionate
04/04/2007EP1769807A1 Graft rejection suppressors
04/04/2007EP1769804A2 Method of increasing bone toughness and stiffness and reducing fractures
04/04/2007EP1769802A1 NFκB ACTION INHIBITOR AND ANTIINFLAMMATORY AGENT, AND STEROID ACTION FORTIFIER
04/04/2007EP1769800A2 Estrogen replacement therapy
04/04/2007EP1769799A2 Pharmaceutical compositions containing steroidal structures and uses thereof
04/04/2007EP1769798A1 New association of agomelatine and a noradrenalin reuptake inhibitor, and pharmaceutical compositions containing them
04/04/2007EP1769797A2 Methods and compositions using cetirizine in combination with leukotriene Inhibitors for treating conditions responsive to leukotriene inhibitiion
04/04/2007EP1769796A1 Novel antibiotics comprising bis(1-aryl-5-tetrazolyl)methane derivatives
04/04/2007EP1769795A2 Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
04/04/2007EP1769794A1 Medicament for preventing and/or treating sleep disorder
04/04/2007EP1769793A1 Therapeutic or preventive drug for diabetes, obesity, or arteriosclerosis
04/04/2007EP1769792A1 Use of a beta-3 adrenoceptor agonist for the treatment of renal and bladder problems
04/04/2007EP1769791A2 Treatment of Alzheimer's disease with cell cycle inhibitors
04/04/2007EP1769789A2 Topical composition comprising capsaicin
04/04/2007EP1769785A1 Dermal penetration enhancers and drug delivery systems involving same
04/04/2007EP1768992A1 Neoglycorandomization and digitoxin analogs
04/04/2007EP1768991A1 Process for the preparation of a1-adenosine receptor agonists
04/04/2007EP1768987A1 (r/s) rifamycin derivatives, their preparation and pharmaceutical compositions
04/04/2007EP1768986A2 Furanopyrimidines
04/04/2007EP1768984A1 Thienopyrimidines useful as aurora kinase inhibitors
04/04/2007EP1768983A2 Fused heterocyclic kinase inhibitors
04/04/2007EP1768982A2 Pyrolo [2,3-d] pyrimidines that modulate ack1 and lck activity
04/04/2007EP1768981A1 Novel pyridodihydropyrazinones method for production and use thereof as medicaments
04/04/2007EP1768979A1 Octahydropyrrolo[2, 3, c]pyridine derivatives and pharmaceutical use thereof